CAR-T cell therapy targeting MUC17 in gastric tumors

Background <p>Chimeric antigen receptor (CAR)-T cell therapy has achieved significant success in hematologic malignancies; however, its efficacy in solid tumors remains limited. A major limitation is the difficulty in identifying suitable target antigens that are abundantly expressed on the surface of tumor cells while sparing life-sustaining normal tissues.</p> Methods <p>We identified MUC17, a membrane-tethered mucin-type glycoprotein with minimal expression in…